{"id":"ei-001","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"EI-001 works by binding to PD-1 on T cells, preventing its interaction with PD-L1 on tumor cells, and thereby enhancing T cell-mediated anti-tumor responses. This mechanism is thought to be responsible for its therapeutic effects in various types of cancer.","oneSentence":"EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:59:26.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT07223229","phase":"PHASE2","title":"Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients","status":"RECRUITING","sponsor":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","startDate":"2025-12-30","conditions":"Non-segmental Vitiligo","enrollment":45},{"nctId":"NCT04994912","phase":"PHASE1","title":"First in Human Study of EI-001 Monoclonal Antibody in Healthy Volunteers","status":"COMPLETED","sponsor":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","startDate":"2021-10-01","conditions":"Healthy","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EI-001","genericName":"EI-001","companyName":"Elixiron Immunotherapeutics (Hong Kong) Ltd.","companyId":"elixiron-immunotherapeutics-hong-kong-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"EI-001 is an immunomodulatory agent that targets the PD-1/PD-L1 axis. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}